Suggested Remit: To appraise the clinical and cost effectiveness of polatuzumab vedotin with rituximab and bendamustine within its marketing authorisation for treating adults with relapsed or refractory diffuse large B-cell lymphoma for whom hematopoietic stem cell transplant is not suitable.
 
Status In progress
Process STA 2018
ID number 1576

Provisional Schedule

Committee meeting: 1 28 January 2020
Committee meeting: 2 24 March 2020
Expected publication 08 April 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Roche
Others Department of Health ad Social Care
  NHS England
Patient carer groups Lymphoma Action
Professional groups Cancer UK
  Royal College o f Radiologists
  Royal College of Physicians

Commentators

Comparator companies Janssen-Cilag
  Servier Lab
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Northern Ireland
  Health Improvement Scotland
  Welsh Health Specialised Services Committee
  Scottish Medicines Consortium
Relevant research groups Institute of Cancer Research: Royal Cancer Hospital

Timeline

Key events during the development of the guidance:

Date Update
23 May 2019 Invitation to participate
26 April 2019 (14:00) Scoping workshop (London)
05 March 2019 - 02 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 April 2017 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance